Selvita S.A., a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.
Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today appointed Dr. Ralf Otto as Chief Operating Officer (COO), effective February 1, 2018.
Storm Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics successful Series A Financing Extension announced in January 2018.
Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Companys headquarters in Cambridge, UK, Dr Atkins also joins Congenicas Board of Directors.
BONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Companys strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Companys CEO since January 2016.
Synpromics Ltd today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.
Glythera Limited is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glytheras portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr Jon Roffey to the companys Scientific Advisory Board (SAB).
sterna biologicals GmbH & Co. KG announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer.
Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.
Targovax ASA (OSE: TRVX) announces that Michael Bogenstaetter has been appointed as the Company’s Chief Business Officer (CBO). He will take up this role in January 2018.